Coronavirus Disease 19 is a global healthcare emergency with high lethality rate. Relevant inflammatory cytokine storm is associated with severity of disease and IL1 inhibition is a cornerstone treatment for hyperinflammatory diseases. We present here the case of a patient with critical COVID-19 successfully treated with IL-1 receptor antagonist (anakinra).
Use of anakinra in severe COVID-19: a case report / G. Filocamo, D. Mangioni, P. Tagliabue, S. Aliberti, G. Costantino, F. Minoia, A. Bandera. - In: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. - ISSN 1201-9712. - 96(2020), pp. 607-609. [10.1016/j.ijid.2020.05.026]
Use of anakinra in severe COVID-19: a case report
D. Mangioni;S. AlibertiConceptualization
;G. CostantinoConceptualization
;A. BanderaUltimo
Conceptualization
2020
Abstract
Coronavirus Disease 19 is a global healthcare emergency with high lethality rate. Relevant inflammatory cytokine storm is associated with severity of disease and IL1 inhibition is a cornerstone treatment for hyperinflammatory diseases. We present here the case of a patient with critical COVID-19 successfully treated with IL-1 receptor antagonist (anakinra).File | Dimensione | Formato | |
---|---|---|---|
PIIS1201971220303337.pdf
accesso riservato
Tipologia:
Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione
517.9 kB
Formato
Adobe PDF
|
517.9 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
PIIS1201971220303337.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
300.74 kB
Formato
Adobe PDF
|
300.74 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.